



## LJMU Research Online

**Boddy, LM, Shelley, J, Knowles, ZR, Stewart, CE and Dawson, EA**

**Physical activity and associations with clinical outcome measures in adults with cystic fibrosis; A systematic review**

<http://researchonline.ljmu.ac.uk/id/eprint/10369/>

### Article

**Citation** (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

**Boddy, LM, Shelley, J, Knowles, ZR, Stewart, CE and Dawson, EA (2019) Physical activity and associations with clinical outcome measures in adults with cystic fibrosis; A systematic review. Journal of Cystic Fibrosis. ISSN 1873-5010**

LJMU has developed [LJMU Research Online](#) for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact [researchonline@ljmu.ac.uk](mailto:researchonline@ljmu.ac.uk)

<http://researchonline.ljmu.ac.uk/>

1 **PHYSICAL ACTIVITY AND ASSOCIATIONS WITH CLINICAL OUTCOME**  
2 **MEASURES IN ADULTS WITH CYSTIC FIBROSIS; A SYSTEMATIC REVIEW.**

3

4 James Shelley<sup>1\*</sup>, Lynne M Boddy<sup>1</sup>, Zoe R Knowles<sup>1</sup>, Claire E Stewart<sup>1</sup>, & Ellen A  
5 Dawson<sup>1</sup>.

6

7 1. Research Institute for Sport and Exercise Sciences, Liverpool John Moores  
8 University, Liverpool, L3 3AF, United Kingdom.

9

10 **RUNNING TITLE: PHYSICAL ACTIVITY IN ADULTS WITH CYSTIC FIBROSIS.**

11

12

13

14

15

16

17

18

19

20

21 **\*Corresponding Author**

22 Mr James Shelley

23 Physical Activity Exchange

24 School of Sports and Exercise Sciences

25 Liverpool John Moores University

26 5 Primrose Hill, Liverpool, L3 2EX

27 United Kingdom

28 j.shelley@2016.ljmu.ac.uk

29

30 **Conflict of Interest**

31 The authors declare that there are no conflicts of interest.

32 **ABSTRACT**

33 *Background:* Physical activity (PA) is important in the management of Cystic Fibrosis (CF) and  
34 is associated with a number of beneficial effects. PA assessment is not commonplace or  
35 consistent clinical practice, therefore understanding of PA in adults with CF remains limited.  
36 The purpose of this review was to evaluate PA levels in this population and compare PA to  
37 global recommendations and non-CF peers.

38 *Methods:* The Preferred Reporting Items for Systematic Reviews and Meta-analyses  
39 guidelines were utilised to inform the review process. Original research was identified and  
40 screened against inclusion/exclusion criteria. Quality was assessed, data extracted and a  
41 narrative synthesis undertaken to describe the findings.

42 *Results:* Adults with CF did not achieve recommended PA guidelines and step count targets  
43 in 5/8 studies where assessment was possible. No significant differences in PA were found  
44 between CF and non-CF peers in 3/5 studies. Associations between PA and improved lung  
45 function were inconsistent with 4/9 studies finding a positive association. Evidence for an  
46 association between PA and higher exercise capacity was stronger with all 4 studies reviewed  
47 reporting a positive association. Quality ratings were low across all studies.

48 *Conclusions:* PA in adults with CF is largely comparable to their non-CF peers, despite being  
49 insufficiently active to achieve PA recommendations. Assessment tools used and outcomes  
50 reported are variable, many of which do not provide sufficient information to assess relevant  
51 components of PA. There is a requirement for high quality studies designed specifically to  
52 explore PA in adults with CF, ideally employing standardised PA assessment methods.

53

54 **KEYWORDS**

55 PRISMA; respiratory disease; exercise; quality of life.

56

57 **ABBREVIATIONS**

58 PA, Physical activity; SB, Sedentary behaviour; PRISMA, Preferred Reporting Items  
59 for Systematic Reviews and Meta-analyses; MVPA, Moderate-Vigorous Physical  
60 Activity; METs, Metabolic Equivalents.

## 61 1. INTRODUCTION

62 Life expectancy of patients with Cystic Fibrosis (CF) continues to increase with improvements  
63 in treatments over recent decades, resulting in a greater proportion of adults living with CF [1].  
64 Physical activity (PA) is associated with a number of potential benefits in the management of  
65 CF including positive effects on lung function [2], mucociliary clearance [3], bone health [4]  
66 and hospitalisation frequency [5]. Higher levels of PA are also associated with improved  
67 exercise capacity [6], which is in turn associated with reduced mortality in patients with CF [7].  
68 PA promotion is therefore recommended as part of the routine management of CF [8,9].  
69 Despite this PA assessment is not common or consistent [8]. However, CF presents patients  
70 with a number of potential barriers to PA including; physical symptoms (breathlessness,  
71 increased cough, fatigue), high treatment burden and low self-efficacy for PA [10].

72 PA can be defined as any bodily movement produced by contraction of skeletal muscle that  
73 substantially increases energy expenditure, this includes leisure-time PA, occupational PA  
74 and exercise [11]. Various self-reported and objective methods are reported in the literature  
75 for the assessment of PA in adults with CF, however inconsistencies in measurement tools,  
76 outcome measures reported and study design used limit our understanding of PA behaviour  
77 and its health associations in this population. It is generally accepted that patients with CF  
78 engage in less PA than their non-CF peers, this is particularly evident for vigorous PA [12],  
79 however this finding is inconsistent across the multiple assessment methods reported in the  
80 literature. Furthermore, little is known about sedentary behaviour (SB) in this population  
81 despite high levels of SB being negatively associated with health outcomes and  
82 cardiometabolic diseases in the general population, even among individuals achieving PA  
83 guidelines of 150 minutes of moderate-to-vigorous PA a week [13]. High levels of SB are  
84 considered as an independent risk factor for cardiovascular disease and mortality [13], yet  
85 remain relatively unexplored in an ageing CF population.

86 There are currently no PA guidelines specifically developed for individuals with CF, although  
87 guidelines for the general population appear to be applicable with some modifications  
88 depending on disease progression [14]. For the purpose of this review, the global physical  
89 activity guidelines outlined by the World Health Organisation (WHO) were used when  
90 interpreting reported PA levels. It is recommended that adults (18-64 years) should take part  
91 in at least 150 minutes of moderate-vigorous intensity aerobic PA (MVPA) or 75 minutes of  
92 vigorous intensity PA throughout the week [15]. The variation in outcome measures reported  
93 in the studies reviewed makes it difficult to compare reported levels of PA to recommended  
94 guidelines, comparison is therefore only possible in a small number of the studies reviewed.  
95 Achieving 10,000 steps daily also provides a reasonable estimate of daily activity and

96 individuals achieving this typically meet the recommendations of 150 minutes MVPA per week  
97 [16]. Therefore assessing step count can help to quantify PA and through the use of the indices  
98 can provide information for screening, surveillance and intervention evaluation [16].

99 A large proportion of the PA research conducted in CF populations has been undertaken with  
100 children and adolescents [8] and may not be transferable to adult populations. It is well  
101 documented that PA declines with age in the general population [17] which may also be  
102 exacerbated by worsening disease severity in CF. Given the increasing life expectancy and  
103 number of adults living with CF, an understanding of PA levels in adult populations is required.  
104 It is important that healthcare professionals are familiar with PA guidelines, engage patients  
105 in conversation around PA and are able provide advice and signpost patients to relevant  
106 resources.

### 107 **1.1 Aims**

108 The purpose of this review therefore, is to: 1) Establish the physical activity levels of adults  
109 with CF. 2) Compare reported PA levels between CF patients and their non-CF peers. 3)  
110 Examine the associations between PA and markers of health in adults with CF.

111

## 112 **2. METHODS**

113 The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)  
114 guidelines were utilised to inform the review process [18]. Studies that assessed PA in adults  
115 with CF and were published from database inception to Feb 28<sup>th</sup> 2018 were identified. An *a*  
116 *priori* defined protocol was utilised to identify relevant articles that were then systematically  
117 screened against inclusion and exclusion criteria. The published protocol can be accessed via  
118 the PROSPERO database (CRD42018088434).

119 A narrative synthesis was performed to provide a summary of the assessment tools used,  
120 outcomes reported and overall quality of PA assessment [19]. An assessment of the quality of  
121 evidence was made to support the strength of the findings and conclusions made. It was not  
122 possible to conduct a meta-analysis due to the wide variation in the methods used to assess  
123 PA, the inconsistency of outcome measures reported and the low quality ratings of the  
124 available literature.


125 **2.1 Search strategy and initial screening**

126 Electronic databases SCOPUS (Elsevier, EMBASE & ScienceDirect), Web of Science,  
127 Medical Literature Analysis and Retrieval System Online (MEDLINE) (Cumulative Index of  
128 Nursing and Allied Health Literature (CINAHL), SportDiscus & Psychinfo) and Oalster grey  
129 literature were searched using search terms individually tailored for each database (Figure 1).  
130 Databases were selected to provide comprehensive coverage of indexed journals, which  
131 publish studies from relevant healthcare and PA fields. Title and abstract screening was  
132 employed to identify relevant articles and remove articles that were not eligible, this was  
133 preferred to applying search limits or 'NOT' terms. Reasons for removing articles at this stage  
134 included; non-CF population, paediatric population, no original data reported, not peer  
135 reviewed and written in languages other than English. No restrictions were applied to the date  
136 of publication, owing to the limited number of studies in a relatively novel field. The search  
137 terms yielded 1166 hits, representing 671 unique articles (Figure 2). A further 565 articles  
138 were removed during title and abstract screening, using the same criteria as above, resulting  
139 in screening of 106 full-text articles. Full-text articles were screened against inclusion and  
140 exclusion criteria, leaving 18 articles for data extraction (Figure 2). Study characteristics are  
141 presented as supplementary material (additional file 1) References of all included papers were  
142 screened, although this did not yield any additional articles.

143 Figure 1 – Boolean search terms

<b>OR</b>	<b>AND</b>
'physical activity'	'Cystic Fibrosis'.
'habitual activity',	
'sedentary behaviour'	
'accelerometers'	
'motion sensors'	
'actigraph'	
'geneactiv'	
'sensewear'	
'activpal'	
'HAES'	
'caltrac'	
'IPAQ'	
& variations on each term	

144 **Figure 2 - PRISMA flowchart**



145

146 **2.2 Application of eligibility criteria**

147 Inclusion criteria included; measurement of physical activity and/or sedentary behaviour (SB)  
 148 using a measurement tool validated for use in the general adult population and/or adults with  
 149 CF. Baseline PA and/or SB reported prior to any interventions. Preferable but not essential  
 150 criteria included; data reported for clinical outcome measures (lung function, exercise  
 151 capacity, quality of life (QoL)).

152

153 Exclusion criteria included; paediatric (<18 years), non-CF or mixed populations where adult  
 154 and paediatric data were not separated, use of non-validated methods for assessing PA and/or  
 155 SB, no reporting of PA and/or SB or no baseline data available. Additionally, studies not written  
 156 in English, providing no original data or that were not peer reviewed were also excluded.  
 157 Studies that were written as abstracts only rather than full papers were also excluded. No  
 158 restrictions were applied for study design. Randomised control trials, interventional and

159 observational studies were considered based on satisfaction of the inclusion/exclusion criteria  
160 outlined above. Five articles were excluded as 'paediatric population' although they reported  
161 data for mixed adult and paediatric populations or defined adults by criteria other than  $\geq 18$   
162 years [6,20–23]. Whilst these articles may contain potentially relevant data the original authors  
163 were not able to provide the data on the request of the reviewers in the given time frame.  
164 Additionally, all studies that were excluded and used accelerometry are listed alongside the  
165 reason for exclusion (additional file 2).

### 166 **2.3 Data extraction**

167 A modified version of the 'Cochrane Data Extraction Form', from the Cochrane Handbook for  
168 Systematic Reviews of Interventions (version 5.1) [24] was used. The form was modified to  
169 include relevant participant characteristics and outcome measures. Two authors (JS, ED)  
170 independently extracted the data, discrepancies were resolved through discussion, with a third  
171 reviewer (LB) where necessary. Extracted information included: Article characteristics; year of  
172 publication, journal, funding source, publication type. Study setting; study population and  
173 participant demographics and baseline characteristics. Study methodology; recruitment and  
174 study completion rates; outcomes and times of measurement. Information for assessment of  
175 the risk of bias.

### 176 **2.4 Risk of bias assessment**

177 Two reviewers (JS, ED) independently assessed the risk of bias for the included studies using  
178 the Cochrane risk of bias tool, agreement was reached between the reviewers although a third  
179 reviewer (LB) was available if required (Table 1).

180 **Table 1 – Risk of bias assessment of studies included for review.**

	Allocation concealment	Blinding of outcome assessors	Blinding of participants & personnel	Sequence Generation	Incomplete outcome data	Selective outcome reporting
<b>Bhudhikanok 1998 [42]</b>	high	high	high	high	low	low
<b>Cox 2016 [5]</b>	high	high	high	high	low	low
<b>Currie 2017 [37]</b>	high	high	high	high	low	low
<b>Decorte 2017 [33]</b>	low	high	high	high	low	low
<b>Elkin 2001 [39]</b>	high	high	high	unclear	low	low
<b>Enright 2004 [38]</b>	low	low	unclear	high	low	low
<b>Enright 2007 [43]</b>	high	low	high	high	low	low
<b>Gruet 2016 [35]</b>	unclear	high	high	high	low	low
<b>Haworth 1999 [34]</b>	high	high	high	high	low	low
<b>Hollander 2005 [32]</b>	high	high	high	high	low	low
<b>Ionescu 2003 [40]</b>	high	high	high	high	low	unclear
<b>Rasekaba 2013 [36]</b>	high	high	high	high	low	low
<b>Savi 2013 [31]</b>	high	high	high	high	low	low
<b>Savi 2015 [30]</b>	high	high	high	high	low	high
<b>Savi 2015 [28]</b>	high	high	high	high	high	high
<b>Street 2006 [41]</b>	high	high	high	high	low	low
<b>Troosters 2009 [12]</b>	high	high	high	high	low	low
<b>Ziai 2016 [29]</b>	high	high	high	high	low	low

181 **2.5 Data synthesis**

182 A narrative synthesis was used to describe the data in three sections; 1) PA levels of adults  
183 with CF in comparison to global PA recommendations, 2) PA levels of adults with CF in  
184 comparison to non-CF peers, 3) The relationship between PA and clinical outcome measures.

185 **2.5.1 Moderate-Vigorous Physical Activity**

186 Studies reporting a measure of PA described with a time unit, were compared to the 150  
187 minutes of MVPA per week recommendation. In studies only measuring PA over 5 days the  
188 150 minutes of MVPA recommendation was interpreted as 30 minutes per day on 5 days of  
189 the week.

190 **2.5.2 Metabolic Equivalent (MET)**

191 MET refers to metabolic equivalent, where 1 MET is the rate of energy expenditure while sitting  
192 at rest and is equivalent to an oxygen uptake of 3.5 millilitres per kilogram (kg) per minute, or  
193 a caloric consumption of 1kcal/kg/hour. METs are used to attempt to classify PA intensity in a  
194 number of studies reviewed, for example, a 3 MET activity expends 3 times the amount of  
195 energy used at rest. For the purposes of this review the following definitions are applied;  
196 moderate intensity (3-6 METs), vigorous activity (>6 METs) [25]. METs can also be expressed  
197 as MET-minutes, whereby the metabolic equivalence of an activity is multiplied by the number  
198 of minutes spent engaging in the activity. For example engaging in an activity of 3 METs for  
199 30 minutes is equal to 90 MET-minutes. Consequently, 150 minutes MVPA per week equate  
200 to 450 MET-minutes per week, therefore recommendations for MET minutes per week are  
201  $\geq 450$  MET-minutes per week.

202 **2.5.3 Steps**

203 Whilst it is not possible to make comparisons with the WHO guidelines, the following indices  
204 were applied to classify PA based on the number of daily steps reported; Sedentary (<5000),  
205 low active (5000-7499), somewhat active (7500-9999), active ( $\geq 10,000$ ), highly active  
206 (>12,500) [16]. Total physical activity described as time spent in weight bearing activity or  
207 walking was reported in two studies. It is not possible to compare levels of PA among adults  
208 with CF to recommended guidelines for MVPA using this data as there is no description of  
209 intensity.

210 **2.5.4 Energy expenditure**

211 Energy expenditure (EE) represents the sum of resting energy expenditure and the thermic  
212 effect of digestion in addition to physical activity [25]. Studies in the current review reported  
213 total energy expenditure (TTE) and not specifically the energy expenditure associated with

214 PA. Whilst it has been proposed that adherence to recommended PA guidelines yields an  
215 energy expenditure of ~1000 kcal-wk<sup>-1</sup>, which is associated with improved health outcomes  
216 [26], TEE alone does not provide suitable information to assess if adults with CF achieved  
217 recommended guidelines for PA.

#### 218 **2.5.5 PA indices**

219 The Baecke and Physical Activity Self-Administered Questionnaire (AQAP) questionnaires  
220 provide a PA index. The work domain classified occupations as; Low activity (1), Moderate  
221 activity (3), High activity (5). Sport and leisure domains were calculated by assigning a MET  
222 value for specified activities and assessing the time spent engaging in such activities again  
223 resulting in a PA score between 1-5. The sum of the three categories (work, sport, leisure)  
224 provides a total PA score between 3-15 [27]. These data do not provide information on minutes  
225 of PA therefore cannot be compared to PA guidelines.

226 **3. RESULTS**

227 **3.1 Reporting of PA in adults with CF**

228 In the 18 studies reviewed 33 separate outcome measures were reported using 11  
 229 assessment tools including 1 accelerometer (SenseWear Pro 3 armband) and 10 separate  
 230 self-report questionnaires (Table 2).

231 **Table 2 – Summary of assessment tools utilised and outcome measures reported.**

Accelerometer	
<b>SenseWear Pro 3 armband</b> [5,12,28–31]	Total energy expenditure (Kcal/day)
	Steps per day
	Total METs
	Total PA (mins/day)
	Light PA (mins/day)
	Moderate PA (mins/day)
	Vigorous PA (mins/day)
Moderate to vigorous PA (mins/day)	
Questionnaire	
<b>Habitual Activity Estimation Scale (HAES)</b> [31]	Total inactivity (min/day)
	Total activity (min/day)
<b>Baecke</b> [32–34]	Activity score
	Activity factor for sedentary lifestyle (1.5, 1.7, 2.1)
	Work index
	Sport index
	Leisure index
<b>Physical Activity self-Administered Questionnaire (AQAP)</b> [35]	Sport index
	Leisure index
	Global index
<b>International Physical Activity Questionnaire (IPAQ)</b> [36]	Work (min/week)
	Transport (min/week)
	Domestic (min/week)
	Leisure (min/week)
	Walking (min/week)
	Moderate (min/week)
	Vigorous (min/week)
<b>Recall questionnaires</b> [37–43]	METs (weekly)
	METs (daily)
	METs (1.5 Light) (hrs/week)
	METs (4 Moderate) (hrs/week)
	METS (6 Hard) (hrs/week)
	METs (10 Very hard) (hrs/week)
	Lying time (min/day)
	Energy expenditure (Kcal/day)

## 232 **3.2 Levels of PA in adults with CF compared to recommended PA guidelines**

233 Comparison between PA levels in adults with CF and global physical activity guidelines was  
234 only possible in 8 [5,12,28-30,,36, 37,43] of the 18 studies reviewed. Adults with CF only met  
235 PA guidelines in 3 [5,36,37] of the 8 studies, only one of which used objective methods to  
236 assess PA [5]. Table 3 displays the findings for the 13 studies which did not include a control  
237 group.

### 238 **3.2.1 Studies reporting objectively assessed PA**

239 Accelerometry was used in 3 of these studies [5,28,29] although only two reported MVPA  
240 [5,28] with a third reporting step count and TEE [29]. Of the two studies reporting MVPA,  
241 participants achieved recommended PA guidelines in one [5]. In the study in which participants  
242 did not achieve recommended PA guidelines, step count was also reported, which would  
243 indicate that patients were 'somewhat active', despite not meeting guidelines for MVPA [28].  
244 Despite using similar assessment methods in groups of comparable disease severity and  
245 participant characteristics the two studies reported different levels of MVPA. The final study  
246 [29] using objective assessment only reported step count, however these values appear to be  
247 similar to those previously reported [28], with both studies reporting 'somewhat active' cohorts  
248 achieving 8874 and 9508 steps respectively.

### 249 **3.2.2 Studies reporting self-reported PA**

250 One study [37] used a 7-day recall questionnaire to assess PA, and whilst this tool has  
251 previously been validated for use in CF [20], reported levels of PA are high in contrast to  
252 objectively assessed PA, with patients exceeding PA recommendations, reporting a mean of  
253 282 minutes of moderate, hard or very hard PA per week. Three studies used the Baecke  
254 questionnaire [32–34], with a fourth using the AQAP [35], all of which report PA as an activity  
255 score and therefore results cannot be compared to PA guidelines. Furthermore one study did  
256 not provide group means, which prevented interpretation [32]. Gruet *et al.* (2016) reported an  
257 overall PA score of 9 (of a possible 15) which may suggest that the population studied were  
258 moderately active [35]. Haworth *et al.* (1999) reported an activity score of 7.6 which likely  
259 represents low levels of activity in the study group [34]. Decorte *et al.* (2017) reported 2.6, 2.3  
260 and 3.2 for work, sport and leisure time indices respectively, which suggests that occupational  
261 activity and engagement in sport were low in the population studied, whilst leisure time activity  
262 was higher [33].

263 Two studies reported mean daily METs [38,40] assessed using recall questionnaires, which  
264 does not provide information for comparison to recommended PA guidelines. Both studies

265 reported similar levels of PA (36.7 and 37.6 daily METs, respectively) which were reported to  
266 be comparable to non-CF young adults [38].

267 Energy expenditure was reported based on self-reported PA in one study [39]. Whilst it is not  
268 possible to make assumptions about PA levels from energy expenditure, the data reported  
269 indicates that TEE in the cohort studied (2071.39 Kcal) is comparable to what could be  
270 predicted for a typical sedentary/low active adult [25].

271 The final studies reported total PA (time spent walking or doing sport) and weight bearing PA  
272 using self-report techniques [41,42]. The data reported did not include any information about  
273 intensity, which again prevents interpretation in the context of WHO recommended guidelines.  
274 The two studies reported considerably different values with Street *et al.* (2006) describing what  
275 could be considered as an active cohort (engaging in 11.3hrs per week of PA, including  
276 walking and sport) whilst data provided by Bhudikanok *et al.* (1998) would suggest that the  
277 cohort were inactive (engaging in 3hrs per week of weight bearing PA). It is possible that the  
278 two report different aspects of PA which is not clear from the methods described.

### 279 **3.2.3 Sedentary behaviour (SB)**

280 No studies assessed SB, although lying time was reported in one study, finding no significant  
281 difference between adults with CF (452.1 mins/day) and their non-CF peers (493.5 mins/day)  
282 ( $P=0.11$ ) [31]. Inactivity, assessed using the HAES, was also reported and was not different  
283 between groups (367 vs. 376.6 mins/day for CF and non-CF respectively ( $P=0.74$ )) [31],  
284 however inactivity describes insufficient levels of PA to meet guidelines and not necessarily  
285 SB [45].

286

287 **Table 3 – Comparison between reported PA in adults with CF and PA recommendations.**

288

289

290 **[Insert Table 3 here – attached as additional file]**

291

292

### 293 **3.3 Levels of PA in adults with CF compared to their non-CF peers**

294 Whilst recommended PA guidelines provide a reference value to assess PA in adults with CF,  
295 it is also well recognised that a large proportion of the general adult population do not meet  
296 recommended PA guidelines [17]. It may therefore be more appropriate to compare adults

297 with CF to comparable non-CF control groups rather than public health guidelines to determine  
298 if differences exist between the cohorts. Five studies [12,30,31,36,43] reported PA levels for  
299 a comparable non-CF control group, PA was therefore compared between these groups  
300 (Table 4).

### 301 **3.3.1 Studies reporting objectively assessed PA**

302 Three studies reported objectively assessed PA [12,30,31]. Time spent engaging in MVPA  
303 was significantly higher in the control group when compared to adults with CF in one study  
304 [12]. No significant differences were found between groups across any other outcome reported  
305 in the remaining studies, additionally, the significant difference found by Troosters *et al.* (2009)  
306 was found in activity above moderate intensity, with no difference at light intensity or in daily  
307 step count [12]. Step count was reported in two studies, neither found a significant difference  
308 between groups, however in both studies the control group would be considered as 'active'  
309 based on the daily number of steps (10281 and 10591 steps respectively), whereas each of  
310 the CF groups failed to meet this threshold (9398 and 9161 steps respectively) [12,30].  
311 Although there is evidence to suggest that there are beneficial effects associated with taking  
312 10,000 steps, cut-points such as this should be interpreted with caution.

### 313 **3.3.2 Studies reporting self-reported PA**

314 Three studies used self-report tools to assess PA [31,36,43]. PA was higher in the non-CF  
315 control group in 1 study [36], there were no significant differences in the remaining 2 studies  
316 [31,43]. The significant difference observed between the CF and non-CF groups was found  
317 for total PA (MET min-week) (5309 and 7808 respectively, ( $P=0.011$ )) [36]. No significant  
318 differences were found between groups for MVPA, additionally, Rasekaba *et al.* (2013)  
319 described comparable levels of PA across domestic, leisure, moderate-vigorous domains, with  
320 reduced total activity being explained by reduced PA in work and transport domains [36]. The  
321 proportion of adults with CF and non-CF controls who met recommended guidelines for PA  
322 was also comparable with 93% in each group [36].

323 One study used both a validated questionnaire (HAES) and an accelerometer [31]. No  
324 significant correlation was observed between PA assessed using the objective or subjective  
325 methods ( $P>0.05$ ), with self-reported PA being over-estimated in both groups, which may  
326 suggest an influence of measurement tool on PA [31].

327 **Table 4 – Comparison between reported levels of PA in adults with CF and**  
328 **comparable non-CF control groups.**

329

330

331 **[Insert Table 4 here – attached as additional file]**

332

333

### 334 **3.4 Relationship between PA and clinical outcome measures**

335 Thirteen studies explored the relationship between PA and other clinical outcome measures  
336 (lung function, body mass index (BMI), exercise capacity, exacerbation frequency)  
337 [5,12,40,42,43,28–31,34,36,37,39]. Whilst the remaining 5 studies [32,33,35,38,41] reported  
338 data on some of these outcome measures no correlations with PA were performed or reported.

#### 339 *3.4.1 Lung Function*

340 Five studies reported on the relationship between lung function expressed as FEV<sub>1</sub> or FEV<sub>1</sub>%  
341 predicted and objectively assessed PA [5,12,28,30,31]. Though MVPA was not different  
342 across categories of disease severity (FEV<sub>1</sub> <40, 40-60, 60-80 >80% predicted), participants  
343 engaging in 30 minutes or more MVPA per day had higher lung function than those engaging  
344 in less than 30 minutes MVPA [5]. Time spent engaging in MVPA was also positively  
345 associated with FEV<sub>1</sub>% predicted ( $P=0.04$ ) [28]. Troosters *et al.* (2009) did not find a  
346 correlation between MVPA and FEV<sub>1</sub>, although number of steps was positively correlated with  
347 near significance with FEV<sub>1</sub> ( $R=0.39$ ,  $P=0.08$ ) [12]. Savi *et al.* (2015) also found no correlation  
348 between MVPA and lung function [30]. MVPA was not reported by Savi *et al.* (2013), who  
349 reported on energy expenditure, finding a significant correlation between FEV<sub>1</sub> and activity  
350 energy expenditure during both week days ( $r=0.436$ ,  $P=0.05$ ) and weekends ( $r=0.435$ ,  
351  $P=0.05$ ) [31].

352 Four studies reported the relationship between lung function and self-reported PA  
353 [36,37,40,43]. No significant difference in FEV<sub>1</sub>% was found between participants who  
354 achieved recommended PA guidelines compared to those who did not achieve guidelines [37].  
355 No relationship was found between FEV<sub>1</sub> and self-reported PA, although low PA was  
356 associated with reduced vital capacity (VC) and total lung capacity (TLC) ( $P<0.01$ ) [43]. Higher  
357 PA (MET·min·week) was associated with better lung function (FEV<sub>1</sub>), although the relationship  
358 was weak ( $R=0.26$ ,  $P<0.05$ ) and not statistically significant when analysing males alone, which  
359 may indicate gender differences in PA levels [36]. Patients with severe impairment (FEV<sub>1</sub>  
360 <45% predicted) were less active than those with mild impairment (FEV<sub>1</sub> >65% predicted)  
361 ( $P<0.01$ ), with no difference between moderate and severe impairment [40].

362                   3.4.2 *Exercise capacity*

363 Four studies explored the relationship between exercise capacity and PA, all of which  
364 assessed PA using objective methods [5,12,30,31]. All found positive associations between  
365 PA (Total PA (( $R=0.51$ ,  $P=0.02$ )) [31] and MVPA (( $\beta=0.59$ ,  $P=0.002$ , ( $R^2=0.32$ )), ( $R=0.44$   
366  $p=0.01$ )) [5,12,30]) and exercise capacity ( $VO_{2peak}$  [5,12,30] and 6-minute walk test distance  
367 [31]). This relationship was not evident when using the HAES questionnaire to assess PA [31].

368                   3.4.3 *Exacerbations*

369 Two studies explored the relationship between exacerbation and hospitalisation frequency  
370 and objectively assessed PA [5,28]. More frequent exacerbations were associated with lower  
371 PA, although this was not significant once corrected for other clinical covariates [28]. Time  
372 spent engaging in MVPA was moderately, yet significantly correlated with reduced need for  
373 hospitalisation ( $r_s=-0.3$ ,  $P=0.05$ ) [5].

374                   3.4.4 *Body composition*

375 Three studies explored the relationship between body composition and self-reported PA  
376 [36,40,43]. Lower PA was associated with lower fat free mass (FFM) [40,43] but not BMI [36].

377 Four studies [34,39,40,42] explored the relationship between self-reported PA and bone  
378 mineral density (BMD), all of which reported a positive association between higher PA and  
379 higher BMD (( $r=0.249$ ,  $P,0.05$ ), ( $r=0.3$ ,  $P<0.01$ ),( $r=0.53$ ,  $P<0.01$ )) [34,39,40] with the exception  
380 of Bhudikanok *et al.* (1998) who reported no association [42].

381                   3.4.5 *Blood glucose control*

382 Two studies reported on the association between blood glucose control and PA, using  
383 objective [29] and self-reported PA assessment [37]. No significant association between blood  
384 glucose control and PA was reported in either study [29,37] .

385                   3.4.6 *Quality of Life (QoL)*

386 Only one study reported on quality of life, finding higher scores for QoL in patients achieving  
387 recommendations for MVPA when compared to those who did not ( $P<0.05$ ) [5].

388 **4. DISCUSSION**

389 In the majority of studies reviewed adults with CF fail to meet recommended PA and step  
390 count guidelines. Non-CF peers also failed to meet guidelines, with comparable levels of PA  
391 between adults with CF and their non-CF peers. There was low quality evidence to support  
392 associations between lung function, exercise capacity and PA. Associations between PA and

393 clinical variables were more evident in studies using objective PA assessments, when  
394 compared to those using self-reported PA.

#### 395 **4.1 Achievement of recommended PA guidelines**

396 Adults with CF did not achieve recommended PA guidelines and daily step count targets in  
397 five out of the eight studies in which comparison to guidelines was possible. However, their  
398 non-CF peers also failed to achieve recommended guidelines in two out of five studies. Many  
399 of the assessment tools used did not provide sufficient information about frequency, intensity  
400 and time of PA to allow for comparison to guidelines. Whilst it is recommended that patients  
401 meet PA guidelines it is also worth noting that a small increase in PA levels is associated with  
402 beneficial effects on health outcomes and risk of all-cause mortality, even when recommended  
403 levels are not achieved. Such health benefits can be achieved by individuals moving from the  
404 category of 'no activity' to 'some levels of' of activity [15].

#### 405 **4.2 Physical activity in adults with CF compared to non-CF peers**

406 No significant differences in PA were found between groups in 3 of the 5 studies with  
407 comparable control groups. The differences observed between groups were reported in work  
408 and transport domains, suggesting variation in lifestyle and employment opportunities in adults  
409 with CF when compared to their non-CF peers in one of these studies [36]. Individuals with  
410 CF are more likely to work in jobs which are sedentary or involve light work, with two thirds of  
411 patients with CF reporting CF as an obstacle to their career, with over half reporting being  
412 limited in their work by CF [46]. Occupational PA in patients with CF may warrant further  
413 investigation. In the second study, the differences between groups were observed at moderate  
414 intensities and above [12]. Classifying PA intensity remains problematic in clinical populations.  
415 Activity intensity is classified using cut-points which are derived using device specific energy  
416 expenditure prediction equations [47], which may not be appropriate for CF populations as no  
417 CF specific cut-points exist. Raw data analysis is recommended as best practice in PA  
418 research [48] and cut-points derived from raw data are available [49], which increases  
419 research control of the data. Unfortunately, these methods were not employed in any of the  
420 studies reviewed and have not been examined in patients with CF to date. Future research  
421 should look to employ these methods when assessing PA in patients with CF.

#### 422 **4.3 The relationship between PA and secondary outcomes**

423 The evidence for an association between PA and lung function was inconsistent with 5/9  
424 finding a positive association. There appears to be stronger evidence for an association  
425 between PA and exercise capacity with all 4 studies reviewed reporting a positive association,  
426 albeit in a small number of low quality studies. Evidence of an association with PA was also

427 inconsistent across all other outcome measures reviewed. Additionally only one study  
428 reviewed reported a measure of QoL.

429 The majority of studies which found an association between PA and lung function used an  
430 objective assessment of PA, with only one study finding an association using self-reported PA.  
431 Likewise, all of the studies finding an association between PA and exercise capacity used  
432 objective PA assessment, whereas the association was not evident when using a self-report  
433 questionnaire. Given the limited number of studies comparing objective and self-reported PA  
434 assessment, it is not possible to assess the influence of assessment tool on the ability to  
435 detect correlations between PA and clinical outcome measures. Though the available data  
436 would suggest that objective PA assessment may be more appropriate than self-reported  
437 methods [31]. Future research should utilise objective PA assessment wherever possible, with  
438 additional self-report methods considered alongside, in order to provide evidence for future  
439 PA guidelines.

440 An additional consideration when exploring the relationship between PA and clinical outcome  
441 measures is that of variation in the population due to the nature of the disease. Patients will  
442 inevitably experience periods of stability and instability, and disease progression and severity  
443 is highly variable within cohorts, all of which presents challenges for monitoring PA.  
444 Exacerbations of CF symptoms and hospitalisation impact levels of PA [50]. This may result  
445 in data attrition if exacerbations occur during study monitoring periods. Additionally, PA  
446 assessed pre, during or post-exacerbation may not accurately reflect habitual PA. Routine  
447 monitoring throughout the year and not just during admissions is required to overcome this  
448 issue. Monitoring devices and cut-points need to be validated for use in CF populations, both  
449 in terms of criterion validity to gold standard measures of PA assessment and in terms of the  
450 ability to discriminate between disease severities. Additional work is required to develop  
451 disease specific cut-points. Alternatively, standardised cut-points should be agreed upon and  
452 adopted universally.

#### 453 **4.4 Variability in reported PA variables**

454 There were a wide range of measurement tools used in the studies reviewed. Five studies  
455 used an objective method [6,11,22–25] with the remaining 12 studies using self-report  
456 questionnaires, in addition to one study using both methods [31]. Comparisons between  
457 studies are difficult due to the large range of outcomes reported (Table 2). There is no  
458 consistent variable (e.g. steps, total PA time, METs) reported meaning analysis of pooled  
459 effects was not possible. There were no consistent findings for PA in comparison to guidelines  
460 or non-CF peers when assessed using different PA assessment methods, suggesting no  
461 difference between the assessment methods used. This may be due to variances in validity

462 and reliability of these assessment methods as well as differences in populations' studied and  
463 study designs. There is therefore a need for an adoption of standardised, objective measures  
464 of PA, with consistent outcomes reported. Standardisation may enable a better understanding  
465 of PA in this cohort and allow for comparisons to be made to global PA recommendations and  
466 non-CF peers.

#### 467 **4.5 Assessment tools utilised**

468 Questionnaires may be useful for large scale epidemiological research, or as secondary  
469 outcome measures of PA, however objective PA assessment should be considered as the  
470 informed choice for PA assessment in clinical practice and research [8]. The IAPQ was the  
471 only self-report tool which allowed PA levels to be compared to guidelines in the current  
472 review. The Baecke questionnaire was the most frequently used questionnaire, used in 3  
473 studies, all of which described low levels of PA in adults with CF. Understanding of PA levels  
474 in adults with CF has previously been based on such studies though it may be possible that  
475 the Baecke questionnaire underestimates PA in this population. The questionnaire is not  
476 disease specific and was developed in healthy, individuals and may not be appropriate for use  
477 in CF populations. Whilst the IPAQ is well validated across multiple populations [51], it is not  
478 valid or appropriate for use in clinical populations such as; breast cancer [52], HIV [53] or  
479 fibromyalgia [54], which highlights the importance of validating tools in the population in which  
480 they are intended to be used. The HAES questionnaire has previously been described as a  
481 valid, reliable and responsive PA assessment tool in adolescents with CF [55]. The current  
482 review only included one study using the HAES questionnaire, the findings of which suggest  
483 that the questionnaire overestimates PA in adults with CF when compared to accelerometry  
484 [31]. The studies in the current review span almost two decades, during which time the  
485 management of CF has changed considerably. Additionally, the assessment of physical  
486 activity has also changed with the increased accessibility and use of accelerometry in the  
487 previous decade. The data available in the current review does not allow for comparisons of  
488 clinical outcome measures and PA assessment throughout this period and caution should be  
489 taken when interpreting data across such a long period.

#### 490 **4.6 Limitations**

491 The quality of data reported in the studies reviewed limits the strength of the conclusions which  
492 can be made from this review, this review therefore highlights the need for further research in  
493 this area. The majority of the studies were graded as low quality, based primarily on a lack of  
494 a control groups and/or randomisation. The majority of studies were not specifically designed  
495 to investigate PA levels, often reporting PA as a secondary outcome measure. The non-  
496 standardised reporting of outcome measures prevents any meta-analysis or collation of data

497 to strengthen the evidence and improve understanding of PA behaviour. Additionally,  
498 assessing the risk of bias in the studies reviewed is problematic. The tools currently available  
499 to assess risk of bias are not designed to assess studies using a cross-sectional design.  
500 Consequently, the assessment of risk of bias and the ability to make recommendations based  
501 on this assessment may be limited when using the tools currently available.

## 502 **CONCLUSIONS**

503 The literature reviewed would suggest that PA in adults with CF is largely comparable to their  
504 non-CF peers, despite being insufficiently active to achieve global PA recommendations. The  
505 choice of PA assessment tool and reported outcomes are highly variable, many of which do  
506 not provide sufficient information about the frequency, intensity or time of PA in adults with  
507 CF. The associations between PA and clinical outcomes appear to be stronger when using  
508 objectively assessed PA when compared to self-reported PA, although there are few studies  
509 available for analysis. The previously reported associations between PA and lung function  
510 appear to be supported by the data reviewed, although a number of studies found no  
511 associations. The association between PA and exercise capacity is also supported by data  
512 reviewed, albeit from a limited number of studies.

513

## 514 **6. FUTURE RECOMMENDATIONS**

515 The current review has highlighted a requirement for high quality studies designed specifically  
516 to explore PA in adults with CF. The increased emphasis on adults with CF is also reflected  
517 by the recently updated European Cystic Fibrosis society (ECFS) best practice guidelines,  
518 who also recognise a shift in focus to adult populations given the current trend in life  
519 expectancy. Whilst this is true for wider CF care it is particularly relevant with regards to PA  
520 assessment, given the lack of available evidence. Standardisation of PA monitoring and  
521 reporting is essential for future research, it has previously been recommended that time spent  
522 engaging in PA of different intensities, time spent sedentary, step count and energy  
523 expenditure should be the minimum standard for reporting PA [8]. A wrist-worn accelerometer  
524 (compliance has previously been shown to be higher when using wrist worn devices [49]),  
525 worn for seven consecutive days during waking hours, using at least 10 hours per day as a  
526 minimum wear time criteria should be used to assess habitual PA [56]. Where possible raw  
527 data analysis should be used to analyse data with outcomes reported as outlined above.  
528 Standardisation will allow for comparisons between cohorts as well as data pooling to improve  
529 statistical precision. Levels of PA and its impact on health and wellbeing in CF are still not  
530 clear in the literature. Which may be attributed to the lack of high-quality research, using  
531 appropriate PA assessment methods to examine PA behaviours and the relationship with

532 clinical outcomes. Further work is therefore needed to fully elucidate the impact of PA in CF,  
533 with an ultimate aim of providing an evidence base to inform guidelines and clinical practice.  
534 The scope of the current review only extends to adults ( $\geq 18$  years), additional reviews are  
535 required to understand any differences between paediatric and adult/mixed populations.

536 The quality of PA assessment would benefit from an approach similar to the European CF  
537 Exercise group's recommended guidelines for exercise testing [57]. This involved experts from  
538 a range of backgrounds from different organisations and geographical areas were involved in  
539 a process to inform the development of the guidelines [57]. The guidance recommends the  
540 standardised use of routine exercising testing in CF care, and whilst this provides an important  
541 assessment of exercise capacity, this is only one component of PA. Further assessment  
542 methods are required to assess habitual PA; a combination of exercise testing, objective and  
543 self-reported PA assessment methods should be considered in clinical practice to screen  
544 participants and inform and evaluate PA interventions.

#### 545 **FUNDING**

546 This research was funded by a Liverpool John Moores University PhD scholarship.

547 **REFERENCES**

- 548 [1] Jeffery Charman, S., Cosgriff, R., Carr, S. A. UK Cystic Fibrosis Registry Annual  
549 Data Report 2016. 2017.
- 550 [2] Schneiderman JE, Wilkes DL, Atenafu EG, Nguyen T, Wells GD, Alarie N, et al.  
551 Longitudinal relationship between physical activity and lung health in patients with  
552 cystic fibrosis. *Eur Respir J* 2014;43. doi:10.1183/09031936.00055513.
- 553 [3] Dwyer TJ, Alison JA, McKeough ZJ, Daviskas E, Bye PTP. Effects of exercise on  
554 respiratory flow and sputum properties in patients with cystic fibrosis. *Chest*  
555 2011;139:870–7. doi:10.1378/chest.10-1158.
- 556 [4] Garcia ST, Sanchez MAG, Cejudo P, Gallego EQ, Dapena J, Jimenez RG, et al.  
557 Bone Health, Daily Physical Activity, and Exercise Tolerance in Patients With Cystic  
558 Fibrosis. *Chest* 2011;140:475–81. doi:10.1378/chest.10-1508.
- 559 [5] Cox NS, Alison JA, Button BM, Wilson JW, Morton JM, Holland AE. Physical activity  
560 participation by adults with cystic fibrosis: An observational study. *Respirology*  
561 2016;21:511–8. doi:10.1111/resp.12719.
- 562 [6] Hebestreit H, Kieser S, Rüdiger S, Schenk T, Junge S, Hebestreit A, et al. Physical  
563 activity is independently related to aerobic capacity in cystic fibrosis. *Eur Respir J*  
564 2006;28:734–9. doi:10.1183/09031936.06.00128605.
- 565 [7] Nixon PA, Orenstein DM, Kelsey SF, Doershuk CF. The prognostic value of exercise  
566 testing in patients with cystic fibrosis. *N Engl J Med* 1992;327:1785–8.  
567 doi:10.1056/NEJM199212173272504.
- 568 [8] Bradley J, O'Neill B, Kent L, Hulzebos EHJ, Arets B, Hebestreit H, et al. Physical  
569 activity assessment in cystic fibrosis: A position statement. *J Cyst Fibros* 2015;14.  
570 doi:10.1016/j.jcf.2015.05.011.
- 571 [9] Cystic Fibrosis Trust. Standards of Care and Good Clinical Practice for the  
572 Physiotherapy Management of Cystic Fibrosis. Third edition 2017. 2017.
- 573 [10] Moola FJ. “CF chatters”: the development of a theoretically informed physical activity  
574 intervention for youth with cystic fibrosis. *Open J Prev Med* 2011;01:109–24.  
575 doi:10.4236/ojpm.2011.13016.
- 576 [11] Howley ET. Type of activity: resistance, aerobic and leisure versus occupational  
577 physical activity. *Med Sci Sports Exerc* 2001;33:S364–9. doi:10.1097/00005768-  
578 200106001-00005.

- 579 [12] Troosters T, Langer D, Vrijzen B, Segers J, Wouters K, Janssens W, et al. Skeletal  
580 muscle weakness, exercise tolerance and physical activity in adults with cystic  
581 fibrosis. *Eur Respir J* 2009;33:99–106. doi:10.1183/09031936.00091607.
- 582 [13] Owen N, Healy GN, Matthews CE, Dunstan DW. Too much sitting: the population  
583 health science of sedentary behavior. *Exerc Sport Sci Rev* 2010;38:105–13.  
584 doi:10.1097/JES.0b013e3181e373a2.
- 585 [14] Swisher Hebestreit, H., Mejia-Downs, A., Lowman, JD., Gruber, W., Nippins, M.,  
586 Alison, J., Schneiderman, J. AK. Exercise and habitual physical activity for people  
587 with Cystic Fibrosis Expert-consensus, evidence-based guide for advising patients.  
588 *Cardiopulm Phys Ther J* 2015;0:1–14. doi:10.1097/CPT.000000000000016.
- 589 [15] World Health Organization. Global Recommendations on Physical Activity for Health.  
590 2012.
- 591 [16] Tudor-Locke C, Bassett DR. How many steps/day are enough? Preliminary  
592 pedometer indices for public health. *Sport Med* 2004;34:1–8. doi:Doi  
593 10.2165/00007256-200434010-00001.
- 594 [17] Hallal PC, Andersen LB, Bull FC, Guthold R, Haskell W, Ekelund U, et al. Global  
595 physical activity levels: Surveillance progress, pitfalls, and prospects. *Lancet*  
596 2012;380:247–57. doi:10.1016/S0140-6736(12)60646-1.
- 597 [18] Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred  
598 reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015  
599 statement. *Syst Rev* 2015;4:1. doi:10.1186/2046-4053-4-1.
- 600 [19] Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on  
601 the Conduct of Narrative Synthesis in Systematic Reviews. A Prod from ESRC  
602 Methods Program 2006:211–9. doi:10.1111/j.1523-536x.1995tb00261.x.
- 603 [20] Ruf KC, Fehn S, Bachmann M, Moeller A, Roth K, Kriemler S, et al. Validation of  
604 activity questionnaires in patients with cystic fibrosis by accelerometry and cycle  
605 ergometry. *BMC Med Res Methodol* 2012;12:43. doi:10.1186/1471-2288-12-43.
- 606 [21] Tejero S, Cejudo P, Sañudo B, Quintana-Gallego E, Sañudo B, Oliva-Pascual-Vaca  
607 A. The role of daily physical activity and nutritional status on bone turnover in cystic  
608 fibrosis: a cross-sectional study. *Braz J Phys Ther* 2016;20:206–12. doi:10.1590/bjpt-  
609 rbf.2014.0154.
- 610 [22] Hebestreit H, Schmid K, Kieser S, Junge S, Ballmann M, Roth K, et al. Quality of life

- 611 is associated with physical activity and fitness in cystic fibrosis. *BMC Pulm Med*  
612 2014;14:26. doi:10.1186/1471-2466-14-26.
- 613 [23] Jantzen A, Opoku-Pare M, Bieli C, Ruf K, Hebestreit H, Moeller A. Perspective on  
614 cystic fibrosis and physical activity: Is there a difference compared to healthy  
615 individuals? *Pediatr Pulmonol* 2016;51. doi:10.1002/ppul.23532.
- 616 [24] Higgins Green S (editors) JPT. *Cochrane Handbook for Systematic Reviews of*  
617 *Interventions* version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011.
- 618 [25] Hills AP, Mokhtar N, Byrne NM. Assessment of Physical Activity and Energy  
619 Expenditure: An Overview of Objective Measures. *Front Nutr* 2014;1:1–16.  
620 doi:10.3389/fnut.2014.00005.
- 621 [26] Paffenbarger RS, Hyde RT, Wing AL, Lee IM, Jung DL, Kampert JB. The Association  
622 of Changes in Physical-Activity Level and Other Life-Style Characteristics with  
623 Mortality among Men. *N Engl J Med* 1993;328:538–45. doi:Doi  
624 10.1056/Nejm199302253280804.
- 625 [27] Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of  
626 habitual physical activity in epidemiological studies. *Am J Clin Nutr* 1982;36:936–42.  
627 doi:10.14814/phy2.12883.
- 628 [28] Savi D, Simmonds N, Di Paolo M, Quattrucci S, Palange P, Banya W, et al.  
629 Relationship between pulmonary exacerbations and daily physical activity in adults  
630 with Cystic Fibrosis. *BMC Pulm Med* 2015;15:151. doi:10.1186/s12890-015-0151-7.
- 631 [29] Ziai S, Coriati A, St-Pierre D, Chabot K, Desjardins K, Leroux C, et al. Glucose  
632 Fluctuations are Not Modulated by the Proportion of Calories from Macronutrients or  
633 Spontaneous Total Energy Expenditure in Adults with Cystic Fibrosis. *Can J Diabetes*  
634 2016;40:389–92. doi:10.1016/j.jcjd.2016.05.007.
- 635 [30] Savi D, Di Paolo M, Simmonds N, Onorati P, Internullo M, Quattrucci S, et al.  
636 Relationship between daily physical activity and aerobic fitness in adults with cystic  
637 fibrosis. *BMC Pulm Med* 2015;15:59. doi:10.1186/s12890-015-0036-9.
- 638 [31] Savi D, Quattrucci S, Internullo M, De Biase R V, Calverley PMA, Palange P.  
639 Measuring habitual physical activity in adults with cystic fibrosis. *Respir Med*  
640 2013;107:1888–94. doi:10.1016/j.rmed.2013.09.012.
- 641 [32] Hollander FM, De Roos NM, De Vries JHM, Van Berkhout FT. Assessment of  
642 nutritional status in adult patients with cystic fibrosis: Whole-body bioimpedance vs

- 643 body mass index, skinfolds, and leg-to-leg bioimpedance. *J Am Diet Assoc*  
644 2005;105:549–55. doi:10.1016/j.jada.2005.01.030.
- 645 [33] Decorte N, Gruet M, Camara B, Quetant S, Mely L, Vallier JM, et al. Absence of calf  
646 muscle metabolism alterations in active cystic fibrosis adults with mild to moderate  
647 lung disease. *J Cyst Fibros* 2017;16. doi:10.1016/j.jcf.2016.05.010.
- 648 [34] Haworth CS, Selby PL, Webb AK, Dodd ME, Musson H, Mc LNR, et al. Low bone  
649 mineral density in adults with cystic fibrosis. *Thorax* 1999;54:961–7.
- 650 [35] Gruet M, Peyre-Tartaruga LA, Mely L, Vallier J-M. The 1-Minute Sit-to-Stand Test in  
651 Adults With Cystic Fibrosis: Correlations With Cardiopulmonary Exercise Test, 6-  
652 Minute Walk Test, and Quadriceps Strength. *Respir Care* 2016;61:1620–8.  
653 doi:10.4187/respcare.04821.
- 654 [36] Rasekaba TM, Button BM, Wilson JW, Holland AE. Reduced physical activity  
655 associated with work and transport in adults with cystic fibrosis. *J Cyst Fibros*  
656 2013;12:229–33. doi:10.1016/j.jcf.2012.09.003.
- 657 [37] Currie S, Greenwood K, Weber L, Khakee H, Legasto M, Tullis E, et al. Physical  
658 Activity Levels in Individuals with Cystic Fibrosis-Related Diabetes. *Physiother Can*  
659 2017;69:171–7. doi:10.3138/ptc.2015-92EP.
- 660 [38] Enright S, Chatham K, Ionescu AA, Unnithan VB, Shale DJ. Inspiratory muscle  
661 training improves lung function and exercise capacity in adults with cystic fibrosis.  
662 *Chest* 2004;126:405–11. doi:10.1378/chest.126.2.405.
- 663 [39] Elkin SL, Fairney A, Burnett S, Kemp M, Kyd P, Burgess J, et al. Vertebral deformities  
664 and low bone mineral density in adults with cystic fibrosis: A cross-sectional study.  
665 *Osteoporos Int* 2001;12. doi:10.1007/s001980170104.
- 666 [40] Ionescu AA, Evans WD, Pettit RJ, Nixon LS, Stone MD, Shale DJ. Hidden depletion  
667 of fat-free mass and bone mineral density in adults with cystic fibrosis. *Chest*  
668 2003;124:2220–8.
- 669 [41] Street ME, Spaggiari C, Ziveri MA, Volta C, Federico G, Baroncelli GI, et al. Analysis  
670 of bone mineral density and turnover in patients with cystic fibrosis: Associations  
671 between the IGF system and inflammatory cytokines. *Horm Res* 2006;66.  
672 doi:10.1159/000094143.
- 673 [42] Bhudhikanok GS, Wang MC, Marcus R, Harkins A, Moss RB, Bachrach LK. Bone  
674 acquisition and loss in children and adults with cystic fibrosis: A longitudinal study. *J*

- 675           Pediatr 1998;133:18–27. doi:Doi 10.1016/S0022-3476(98)70172-6.
- 676 [43]   Enright S, Chatham K, Ionescu AA, Unnithan VB, Shale DJ. The influence of body  
677           composition on respiratory muscle, lung function and diaphragm thickness in adults  
678           with cystic fibrosis. *J Cyst Fibros* 2007;6. doi:10.1016/j.jcf.2007.02.006.
- 679 [44]   Cox NS, Alison JA, Button BM, Wilson JW, Morton JM, Holland AE. Physical activity  
680           participation by adults with cystic fibrosis: An observational study. *Respirology*  
681           2016;21. doi:10.1111/resp.12719.
- 682 [45]   Tremblay MS, Aubert S, Barnes JD, Saunders TJ, Carson V, Latimer-Cheung AE, et  
683           al. Sedentary Behavior Research Network (SBRN) - Terminology Consensus Project  
684           process and outcome. *Int J Behav Nutr Phys Act* 2017;14:1–17. doi:10.1186/s12966-  
685           017-0525-8.
- 686 [46]   Laborde-Castérot H, Donnay C, Chapron J, Burgel PR, Kanaan R, Honoré I, et al.  
687           Employment and work disability in adults with cystic fibrosis. *J Cyst Fibros*  
688           2012;11:137–43. doi:10.1016/j.jcf.2011.10.008.
- 689 [47]   Ridgers ND, Fairclough S. Assessing free-living physical activity using accelerometry:  
690           Practical issues for researchers and practitioners. *Eur J Sport Sci* 2011;11:205–13.  
691           doi:Pii 93735128910.1080/17461391.2010.501116.
- 692 [48]   Heil DP, Brage S, Rothney MP. Modeling physical activity outcomes from wearable  
693           monitors. *Med Sci Sports Exerc* 2012;44:50–60.  
694           doi:10.1249/MSS.0b013e3182399dcc.
- 695 [49]   Hildebrand M, Van Hees VT, Hansen BH, Ekelund U. Age group comparability of raw  
696           accelerometer output from wrist-and hip-worn monitors. *Med Sci Sports Exerc*  
697           2014;46:1816–24. doi:10.1249/MSS.0000000000000289.
- 698 [50]   Wieboldt J, Atallah L, Kelly JL, Shrikrishna D, Gyi KM, Lo B, et al. Effect of acute  
699           exacerbations on skeletal muscle strength and physical activity in cystic fibrosis. *J*  
700           *Cyst Fibros* 2012;11:209–15. doi:10.1016/j.jcf.2011.12.001.
- 701 [51]   Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al.  
702           International physical activity questionnaire: 12-Country reliability and validity. *Med*  
703           *Sci Sports Exerc* 2003. doi:10.1249/01.MSS.0000078924.61453.FB.
- 704 [52]   Johnson-Koslow M, Sallis JF, Gilpin EA, Rock CL, Pierce JP. Comparative validation  
705           of the IPAQ and the 7-day PAR among women diagnosed with breast cancer. *Int J*  
706           *Behav Nutr Phys Act* 2006. doi:10.1186/1479-5868-3-7.

- 707 [53] Fillipas S, Cicuttini F, Holland AE, Cherry CL. The International Physical Activity  
708 Questionnaire Overestimates Moderate and Vigorous Physical Activity in HIV-Infected  
709 Individuals Compared With Accelerometry. *J Assoc Nurses AIDS Care* 2010.  
710 doi:10.1016/j.jana.2009.11.003.
- 711 [54] Kaleth AS, Ang DC, Chakr R, Tong Y. Validity and reliability of community health  
712 activities model program for seniors and short-form international physical activity  
713 questionnaire as physical activity assessment tools in patients with fibromyalgia.  
714 *Disabil Rehabil* 2010. doi:10.3109/09638280903166352.
- 715 [55] Wells GD, Wilkes DL, Schneiderman-Walker J, Elmi M, Tullis E, Lands LC, et al.  
716 Reliability and validity of the Habitual Activity Estimation Scale (HAES) in patients with  
717 cystic fibrosis. *Pediatr Pulmonol* 2008;43:345–53. doi:10.1002/ppul.20737.
- 718 [56] Matthews CE, Hagströmer M, M PD, Bowles HR. Best Practices for Using Physical  
719 Activity Monitors. *Med Sci Sports Exerc* 2013;44:1–17.  
720 doi:10.1249/MSS.0b013e3182399e5b.BEST.
- 721 [57] Hebestreit H, Arets HGM, Aurora P, Boas S, Cerny F, Hulzebos EHJ, et al. Statement  
722 on Exercise Testing in Cystic Fibrosis. *Respiration* 2015;90:332–51.  
723 doi:10.1159/000439057.
- 724